Radiation after chemoimmunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the esophagus that has not spread to distant organs.
- Your tumor is considered resectable by the surgical team.
- You have completed initial chemoimmunotherapy and still have measurable disease.
- You are in good overall health with an ECOG performance status of 0 or 1.
- Your blood counts, kidney function, and liver function are within acceptable ranges.
- You have not had prior radiation to the chest or prior treatment with a PD-1 or similar drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
This trial tests a combination of short-course radiation, an immunotherapy drug called tislelizumab, and chemotherapy before surgery for esophageal cancer that has spread to nearby lymph nodes but hasn't spread to distant organs. The goal is to shrink the tumor before surgery and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.